Optimizing Empiric Antibiotic Therapy in Patients with Severe β-Lactam Allergy

被引:22
|
作者
Koliscak, Lindsey P. [1 ,2 ]
Johnson, James W. [1 ,3 ]
Beardsley, James R. [1 ]
Miller, David P. [3 ]
Williamson, John C. [1 ,3 ]
Luther, Vera P. [3 ]
Ohl, Christopher A. [3 ]
机构
[1] Wake Forest Baptist Hlth, Dept Pharm, Winston Salem, NC 27106 USA
[2] Wingate Univ, Sch Pharm, Wingate, NC USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
关键词
MULTIDRUG-RESISTANT; RISK-FACTORS; INFECTION; IMPACT; CARBAPENEM; MORTALITY; BACTERIA;
D O I
10.1128/AAC.01202-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antibiotic selection is challenging in patients with severe beta-lactam allergy due to declining reliability of alternate antibiotics. Organisms isolated from these patients may exhibit unique resistance phenotypes. The objective of this study was to determine which alternate antibiotics or combinations provide adequate empirical therapy for patients with beta-lactam allergy who develop Gram-negative infections at our institution. We further sought to determine the effects of risk factors for drug resistance on empirical adequacy. A retrospective analysis was conducted for adult patients hospitalized from September 2009 to May 2010 who had a severe beta-lactam allergy and a urine, blood, or respiratory culture positive for a Gram-negative organism and who met predefined criteria for infection. Patient characteristics, culture and susceptibility data, and predefined risk factors for antibiotic resistance were collected. Adequacies of beta-lactam and alternate antibiotics were compared for all infections and selected subsets. The primary outcome was adequacy of each alternate antibiotic or combination for all infections. One hundred sixteen infections (40 pneumonias, 67 urinary tract infections, and 9 bacteremias) were identified. Single alternate agents were adequate less frequently than beta-lactams and combination regimens. Only in cases without risk factors for resistance did single-agent regimens demonstrate acceptable adequacy rates; each factor conferred a doubling of risk for resistance. Resistance risk factors should be considered in selecting empirical antibiotics for Gram-negative pathogens in patients unable to take beta-lactams due to severe allergy.
引用
收藏
页码:5918 / 5923
页数:6
相关论文
共 50 条
  • [11] DOUBLE BETA-LACTAM REGIMEN COMPARED TO AN AMINOGLYCOSIDE BETA-LACTAM REGIMEN AS EMPIRIC ANTIBIOTIC-THERAPY FOR FEBRILE GRANULOCYTOPENIC CANCER-PATIENTS
    JOSHI, JH
    NEWMAN, KA
    BROWN, BW
    FINLEY, RS
    RUXER, RL
    MOODY, MA
    SCHIMPFF, SC
    SUPPORTIVE CARE IN CANCER, 1993, 1 (04) : 186 - 194
  • [12] Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
    Stephen Y. Liang
    Anand Kumar
    Current Infectious Disease Reports, 2015, 17
  • [13] Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
    Liang, Stephen Y.
    Kumar, Anand
    CURRENT INFECTIOUS DISEASE REPORTS, 2015, 17 (07)
  • [14] Optimizing β-lactam-containing antibiotic combination therapy for the treatment of Buruli ulcer
    D'Agate, Salvatore
    Velickovic, Peter
    Garcia-Barrios, Noelia
    Ramon-Garcia, Santiago
    Della Pasqua, Oscar
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 91 (01) : 179 - 189
  • [15] Empiric therapy of bacterial infections in patients with severe neutropenia
    Glauser, M
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (03) : 467 - 472
  • [16] The effect of empiric antibiotic therapy on mortality in debilitated patients with dementia
    S. Reisfeld
    M. Paul
    B. S. Gottesman
    P. Shitrit
    L. Leibovici
    M. Chowers
    European Journal of Clinical Microbiology & Infectious Diseases, 2011, 30 : 813 - 818
  • [17] DURATION OF EMPIRIC ANTIBIOTIC THERAPY IN GRANULOCYTOPENIC CANCER-PATIENTS
    PIZZO, P
    ROBICHAUD, K
    GILL, F
    WITEBSKY, F
    LEVINE, A
    MACLOWRY, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 384 - 384
  • [18] The effect of empiric antibiotic therapy on mortality in debilitated patients with dementia
    Reisfeld, S.
    Paul, M.
    Gottesman, B. S.
    Shitrit, P.
    Leibovici, L.
    Chowers, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (06) : 813 - 818
  • [19] EMPIRIC ANTIBIOTIC-THERAPY FOR GRANULOCYTOPENIC CANCER-PATIENTS
    SCHIMPFF, SC
    AMERICAN JOURNAL OF MEDICINE, 1986, 80 (5C): : 13 - 20
  • [20] DURATION OF EMPIRIC ANTIBIOTIC-THERAPY IN GRANULOCYTOPENIC PATIENTS WITH CANCER
    PIZZO, PA
    ROBICHAUD, KJ
    GILL, FA
    WITEBSKY, FG
    LEVINE, AS
    DEISSEROTH, AB
    GLAUBIGER, DL
    MACLOWRY, JD
    MAGRATH, IT
    POPLACK, DG
    SIMON, RM
    AMERICAN JOURNAL OF MEDICINE, 1979, 67 (02): : 194 - 200